|
|
| (32 intermediate revisions by 4 users not shown) |
| Line 1: |
Line 1: |
| Hello. I am marking this shared space off as a private, experimental, part-voyeuristic space. Please do not try to infer too much from perceived aberrant aspects if you value your time :)
| | [[File:clarity-user-wiki-personal.jpg|center|thumb|400px|"Mind is like the void in which there is no confusion or evil, as when the sun wheels through it, shining upon the four corners of the world. For when the sun rises and illuminates the whole earth, the void gains not in brilliance; and, when the sun sets, the void does not darken. The phenomena of light and dark alternate with each other, but the nature of the void remains unchanged."]] |
|
| |
|
| == Brainstorm Sesh Results ==
| |
| ''Following extensive discussions with [[User:Kenan|Kenan]] @ PS17 week, taken via phone on the flight back :P''
| |
|
| |
|
| '''thats some dope shit right here.''' --[[User:Kenan|Kenan]] ([[User talk:Kenan|talk]]) 04:24, 27 April 2017 (CEST)
| |
|
| |
|
| * Breakdown all pharmacology sections into "Pharmacokinetics", "Pharmacodynamics" with corresponding "Sci Portal" pages providing both quick + accessible versions as well as comprehensive ones (start with classic psys)
| | ==About== |
| * Add Structure Activity Relationship (SAR) sections to all pages, either as its own section or a subsection of "Chemistry"
| | Hello. I am marking this shared space off as a private, experimental, part-voyeuristic space. Please do not try to infer too much from perceived aberrant aspects if you value your time and/or sanity :) |
| * More development of basic biological and pharmacological content that users can access through our descriptions (i.e. Pages like "Synapse", "Postsynaptic Density", "Autoreceptor", "Ionotropic vs GPCRs", "Blood-brain barrier", the different subtypes of monoamine receptors like 5HT2B, 5HT1A, 5HT2A/C, etc)
| |
| * More potential user-valued sections like "History and Culture", "Behavioral Toxicity", "Common Myths/Misconceptions and FAQs" etc to increase page/content diversity to differentiate ourselves from other sites
| |
| * Reagent Testing Section for commonly adulterated/misrepresented substances.
| |
| * Creation of "Recommended Books and Media" section with Amazon affiliate links for shared PW account?
| |
| * "Featured article" panel on main page? More indicators of dynamic nature of content development and a sense of an editorial board.
| |
| * Feature contraindications and dangerous interactions more prominently/visibly i.e. Tripsit
| |
| * Standardize "Physical Effects" to ground them in a medical framework.
| |
| * Automatically reiteratable substanceboxes that uses mathematical algorithms to calculate different doses based on salt form.
| |
| * Anonymous feedback links under each SubstanceBox?
| |
| * Upgrade forum to more modern, user alluring one. Then have it more directly integrated into the pages so users who are afraid to edit have a gateway to providing feedback and input (will also encourage more active participation from userbase who have the potential to become contributors but currently aren't due to intimidation factor)
| |
| * Autofill Summary boxes based on sections edited, then require editors to provide summaries
| |
| * Red/yellow/green strips or some other indicator above substanceboxes denoting "novelty" or "verified information" or "page reliability" form? To help sort out truly novel RCs which don't have any scientific literature produced on them vs. those produced through literature mining and have a higher or lower speculated risk of unpredictable effects based on Structure-Activity Relationship analysis.
| |
| * PubChem as reference to all IUPAC and systematic names
| |
| * "Announcements" or "Bulletin" pages for editors to see new content initiatives/guidelines.
| |
| * Partner with EnergyControl or other drug analysis service to link to on our pages for commonly counterfeited/adulterated substances.
| |
| * highlight search box main result with translucent blue panel for increased visibility?
| |
| * Change psychedelic tolerance baselines to the standard online "two week" chart
| |
| * Boilerplate basic coverage of all basic RC psychs w/tags to cite incompleteness?
| |
| * Monthly high scores? "Featured User" Panel on Mainpage, etc.
| |
| * "Common drug myths" and FAQs page to clear basic misconceptions userbase may have, ranging from basic to nuanced.
| |
| * Further development of PW style and formatting standards
| |
| * Citation conversion guide?
| |
| * PW t-shirt line of "Drug Molecules" print? (collective fund)
| |
| * Start development of basic "philosophy of mind" sections?
| |
| * More collaboration with Global Psychedelics Network?
| |
| * Start development of monthly newsletter/newsfeed on Psynthes.is?
| |
| * Change "Legal issues" to "Legality" so as to not imply inherent illegality?
| |
| * "History of Prohibition" page (start with alcohol?)
| |
|
| |
|
| == Portfolio ==
| | [[File:OM_MANI_PADME_HUM-bw.svg|400px|center]] |
| Included below is a list of substance pages which I have either started from scratch or made substantial edits to existing pages since joining the site in October 2016. While I consider these to meet my minimal personal standards for publication, I still consider most of these pages as being works-in-progress (with some more-so than others) and intend to continue developing them in the future as time permits (as I currently do this in my spare time).
| |
| | |
| {|
| |
| |-
| |
| |
| |
| *'''[[6-APB]]'''
| |
| *'''[[6-APDB]]'''
| |
| *'''[[3-MeO-PCP]]'''
| |
| *'''[[3-MeO-PCE]]'''
| |
| *'''[[a-PHP]]'''
| |
| *'''[[a-PVP]]'''
| |
| *'''[[5-MAPB]]'''
| |
| ||
| |
| *'''[[MPT]]'''
| |
| *'''[[MET]]'''
| |
| *'''[[4-AcO-DET]]'''
| |
| *'''[[4-HO-DPT]]'''
| |
| *'''[[4-HO-EPT]]'''
| |
| *'''[[4-HO-MPT]]'''
| |
| *'''[[2-FA]]'''
| |
| || | |
| *'''[[2-FMA]]'''
| |
| *'''[[3-FA]]'''
| |
| *'''[[3-FEA]]'''
| |
| *'''[[4-FMA]]'''
| |
| *'''[[Ethylone]]'''
| |
| *'''[[Butylone]]'''
| |
| *'''[[MDEA]]'''
| |
| ||
| |
| *'''[[TMA-2]]'''
| |
| *'''[[TMA-6]]'''
| |
| *'''[[Prolintane]]'''
| |
| *'''[[HDMP-28]]'''
| |
| *'''[[RTI-111]]''' (Dichloropane)
| |
| *'''[[Desoxypipradol]]''' (2-DPMP)
| |
| *'''[[Propylhexedrine]]'''
| |
| |}
| |
| | |
| ''For a more comprehensive list of the contributions and edits I have made to this site, please see this [https://psychonautwiki.org/w/index.php?limit=500&tagfilter=&title=Special%3AContributions&contribs=user&target=Clarity&namespace=&tagfilter=&year=207&month=-1 link].''
| |
| | |
| ==Selected Experience Reports (i.e. Writing Samples)==
| |
| *[https://www.reddit.com/r/KnowTheDose/comments/55o99y/ktd_official_experience_reports/ KTD Official Experience Reports "3-MeO-PCE" (Trial I)]
| |
| *[https://www.reddit.com/r/KnowTheDose/comments/54c1uk/ktd_official_experience_reports/ KTD Official Experience Reports "RTI-111" (Trial III)]
| |
| | |
| ==Currently Reading==
| |
| * [https://www.iidc.indiana.edu/pages/Social-Communication-and-Language-Characteristics-Associated-with-High-Functioning-Verbal-Children-and-Adults-with-ASD Social Communication and Language Characteristics Associated with High Functioning, Verbal Children and Adults with ASD]
| |
| * [https://pdfs.semanticscholar.org/7b8d/3ca63f676e2306ba33dc4350a9d659c3ec6b.pdf Garfield, J. L., & Priest, G. (2003). Nargajuna and the Limits of Thought NA, 53(1), 1–22.]
| |
| * [https://www.quora.com/Why-is-Alexander-Grothendieck-revered-by-mathematicians Why is Alexander Grothendieck revered by mathematicians? (Quora)]
| |
| * [http://www.math.harvard.edu/~mazur/papers/Thinking.about.Grothendieck(5).pdf Mazur, B. (2016). '''''Thinking about Grothendieck'''''. Harvard Math.] (on recommendation from a friend)
| |
| * [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345542/pdf/yjbm_88_1_81.pdf Van Schalkwyk, G. I., Klingensmith, K., & Volkmar, F. R. (2015). '''''Gender identity and autism spectrum disorders.''''' The Yale Journal of Biology and Medicine, 88(1), 81.]
| |
| | |
| ==Reading List==
| |
| Listed by (general) orders of engagement.
| |
| ===Papers===
| |
| ====Research====
| |
| * Lai MC, Lombardo MV, Pasco G, Ruigrok ANV, Wheelwright SJ, et al. (2011). '''''[http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0020835 A Behavioral Comparison of Male and Female Adults with High Functioning Autism Spectrum Conditions]'''''. PLOS ONE 6(6): e20835. https://doi.org/10.1371/journal.pone.0020835.
| |
| * [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345542/pdf/yjbm_88_1_81.pdf Van Schalkwyk, G. I., Klingensmith, K., & Volkmar, F. R. (2015). '''''Gender identity and autism spectrum disorders.''''' The Yale Journal of Biology and Medicine, 88(1), 81.]
| |
| * Just, M. A., Cherkassky, V. L., Keller, T. A., & Minshew, N. J. (2004). '''''Cortical activation and synchronization during sentence comprehension in high-functioning autism: evidence of underconnectivity.''''' Brain, 127(8), 1811-1821. https://doi.org/10.1093/brain/awh199
| |
| * Ozonoff, S., Rogers, S. J., & Pennington, B. F. (1991). '''''Asperger's syndrome: Evidence of an empirical distinction from high‐functioning autism.''''' Journal of Child Psychology and Psychiatry, 32(7), 1107-1122. https://doi.org/10.1111/j.1469-7610.1991.tb00352.x
| |
| ====Misc.====
| |
| * [http://www.math.harvard.edu/~mazur/papers/Thinking.about.Grothendieck(5).pdf Mazur, B. (2016). '''''Thinking about Grothendieck'''''. Harvard Math.] (on recommendation from a friend)
| |
| * [https://pdfs.semanticscholar.org/7b8d/3ca63f676e2306ba33dc4350a9d659c3ec6b.pdf Garfield, J. L., & Priest, G. (2003). Nargajuna and the Limits of Thought NA, 53(1), 1–22.]
| |
| ===Books===
| |
| * '''[http://www-dev.wisdompubs.com/sites/default/files/preview/Nagarjuna's-Middle-Way-Book-Preview-R.pdf Nagarjuna's Middle Way (Mûlamadhyamakakârikâ) (Book Preview R)]'''
| |
| * Wallace, B. A. (Ed.). (1997). '''''[https://selfdefinition.org/tibetan/Santideva-A-Guide-To-The-Bodhisattva-Way-Of-Life.pdf A Guide to the Bodhisattva's Way of Life]'''''. Shambhala.
| |
| ===Pages===
| |
| * [https://www.iidc.indiana.edu/pages/Social-Communication-and-Language-Characteristics-Associated-with-High-Functioning-Verbal-Children-and-Adults-with-ASD Social Communication and Language Characteristics Associated with High Functioning, Verbal Children and Adults with ASD]
| |
| * https://en.wikipedia.org/wiki/Thomas_Szasz
| |
| * https://en.wikipedia.org/wiki/Capitalism_and_Schizophrenia
| |
|
| |
|
| ==Researched Materials== | | ==Researched Materials== |
| | ''These are materials I have conducted extensive archival research on. If you have any questions about the effects or properties of the substances below, feel free to ask.'' |
| <noinclude>__NOTOC__</noinclude><onlyinclude> | | <noinclude>__NOTOC__</noinclude><onlyinclude> |
| <div class='flex-panel'> | | <div class='flex-panel'> |
| Line 130: |
Line 31: |
| * [[MET]] | | * [[MET]] |
| * [[MPT]] | | * [[MPT]] |
| * [[EPT]]
| |
| * [[DPT]] | | * [[DPT]] |
| * [[DiPT]] | | * [[DiPT]] |
| Line 141: |
Line 41: |
| * [[4-HO-MET]] (''Metocin'') | | * [[4-HO-MET]] (''Metocin'') |
| * [[4-HO-MiPT]] (''Miprocin'') | | * [[4-HO-MiPT]] (''Miprocin'') |
| | * [[4-HO-DET]] |
| * [[4-HO-DPT]] | | * [[4-HO-DPT]] |
| * [[4-AcO-DMT]] (''Psilacetin'') | | * [[4-AcO-DMT]] (''Psilacetin'') |
| | * [[4-AcO-DiPT]] (''Ipracetin'') |
| * [[4-AcO-MET]] (''Metacetin'', ''Azomet'') | | * [[4-AcO-MET]] (''Metacetin'', ''Azomet'') |
| * [[4-AcO-MiPT]] (''Mipracetin'')
| |
| * [[5-MeO-DMT]] | | * [[5-MeO-DMT]] |
| * [[5-MeO-MiPT]] (''Moxy'') | | * [[5-MeO-MiPT]] (''Moxy'') |
| Line 196: |
Line 97: |
| * [[Cannabis]] | | * [[Cannabis]] |
| * [[Changa]] | | * [[Changa]] |
| * [[peganum harmala|Syrian Rue]] | | * [[Syrian Rue]] |
| * [[LSA#Morning glory seeds|Morning Glory]] | | * [[LSA#Morning glory seeds|Morning Glory]] |
| * [[Banisteriopsis caapi]] | | * [[Banisteriopsis caapi]] |
| * [[DMT#Mimosa hostilis root bark|Mimosa hostilis]]
| |
| * [[Psilocin#Psilocybin mushrooms|Psilocybe mushroom]] | | * [[Psilocin#Psilocybin mushrooms|Psilocybe mushroom]] |
| * [[Salvinorin_A#Salvia_divinorum|Salvia divinorum]] | | * [[Salvinorin_A#Salvia_divinorum|Salvia divinorum]] |
| Line 213: |
Line 113: |
| * [[Ketamine]] | | * [[Ketamine]] |
| * [[Methoxetamine]] (''MXE'') | | * [[Methoxetamine]] (''MXE'') |
| * [[2-Oxo-PCM|2'-Oxo-PCM]] (''O-PCM'' / ''Deschloroketamine (DCK)'' / ''DXE'') | | * [[2-Oxo-PCM|2'-Oxo-PCM]] (''O-PCM'' / ''Deschloroketamine (DCK)'') |
| * [[2-Oxo-PCE|2'-Oxo-PCE]] (''O-PCE'') | | * [[2-Oxo-PCE|2'-Oxo-PCE]] (''O-PCE'') |
| * [[3-MeO-PCP]] | | * [[3-MeO-PCP]] |
| Line 222: |
Line 122: |
| <h4 class="media-heading">[[Morphinan]]s</h4> | | <h4 class="media-heading">[[Morphinan]]s</h4> |
| * [[Dextromethorphan]] (''DXM'') | | * [[Dextromethorphan]] (''DXM'') |
| * [[Dextrorphan]] (''DXO'')
| |
| </li> | | </li> |
|
| |
|
| <li class="featured list-item"> | | <li class="featured list-item"> |
| <h4 class="media-heading">Others</h4> | | <h4 class="media-heading">Others</h4> |
| * [[Salvinorin A]]
| |
| * [[Salvinorin B methoxymethyl ether]]
| |
| * [[Nitrous oxide]] | | * [[Nitrous oxide]] |
| </li> | | </li> |
| Line 312: |
Line 209: |
| * [[MDAI]] | | * [[MDAI]] |
| * [[Methylone]] (''βk-MDMA'') | | * [[Methylone]] (''βk-MDMA'') |
| * [[5-APB]]
| |
| * [[5-APDB]]
| |
| * [[5-MAPB]] | | * [[5-MAPB]] |
| * [[6-APB]] | | * [[6-APB]] |
